CA2237524A1 - Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease - Google Patents
Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease Download PDFInfo
- Publication number
- CA2237524A1 CA2237524A1 CA002237524A CA2237524A CA2237524A1 CA 2237524 A1 CA2237524 A1 CA 2237524A1 CA 002237524 A CA002237524 A CA 002237524A CA 2237524 A CA2237524 A CA 2237524A CA 2237524 A1 CA2237524 A1 CA 2237524A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- aryl
- hydroxycarboxamide
- oxa
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne des molécules macrocycliques qui inhibent les métalloprotéinases, y compris l'agrécanase, et la production du facteur de nécrose tumorale (TNF). En particulier, les composés en question inhibent les métalloprotéinases intervenant dans la dégradation des tissus, d'une part, et la libération du TNF, d'autre part. On décrit par ailleurs des compositions pharmaceutiques renfermant ces composés et un certain nombre de procédés relatifs à l'utilisation de ces composés pour le traitement des maladies inflammatoires.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US668495P | 1995-11-14 | 1995-11-14 | |
US60/006,684 | 1995-11-14 | ||
US64690296A | 1996-05-08 | 1996-05-08 | |
US08/646,902 | 1996-05-08 | ||
US74343996A | 1996-11-01 | 1996-11-01 | |
US08/743,439 | 1996-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2237524A1 true CA2237524A1 (fr) | 1997-05-22 |
Family
ID=27358171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002237524A Abandoned CA2237524A1 (fr) | 1995-11-14 | 1996-11-13 | Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0863885A2 (fr) |
JP (1) | JP2000502050A (fr) |
CN (1) | CN1202161A (fr) |
BR (1) | BR9611563A (fr) |
CA (1) | CA2237524A1 (fr) |
CZ (1) | CZ144798A3 (fr) |
EE (1) | EE9800115A (fr) |
HR (1) | HRP960533A2 (fr) |
HU (1) | HUP0201479A2 (fr) |
IL (1) | IL124366A0 (fr) |
LV (1) | LV12167B (fr) |
MX (1) | MX9803851A (fr) |
NO (1) | NO982185L (fr) |
PL (1) | PL326714A1 (fr) |
SI (1) | SI9620120A (fr) |
SK (1) | SK63498A3 (fr) |
WO (1) | WO1997018207A2 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281352B1 (en) | 1995-11-14 | 2001-08-28 | Dupont Pharmaceuticals Company | Macrocyclic compounds as metalloprotease inhibitors |
US5952320A (en) * | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
ZA9820B (en) * | 1997-01-07 | 1998-07-02 | Abbott Lab | Macrocyclic inhibitors of matrix metalloproteinases and tnf x secretion |
US5985911A (en) * | 1997-01-07 | 1999-11-16 | Abbott Laboratories | C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion |
EP1068224B1 (fr) | 1998-03-31 | 2005-05-11 | Bristol-Myers Squibb Pharma Company | Produits pharmaceutiques pour l'imagerie de troubles angiogenes |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
CA2333551A1 (fr) | 1998-06-11 | 1999-12-16 | Zhe Wang | Procede de preparation d'inhibiteurs macrocycliques des metalloproteases |
NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
WO2000035887A2 (fr) | 1998-12-18 | 2000-06-22 | Du Pont Pharm Co | Medicaments antagonistes du recepteur de la vitronectine |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6511648B2 (en) | 1998-12-18 | 2003-01-28 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6649377B1 (en) | 1999-05-10 | 2003-11-18 | Syntex (U.S.A.) Llc | Human aggrecanase and nucleic acid compositions encoding the same |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US6989139B2 (en) * | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
AU783857B2 (en) | 2000-06-01 | 2005-12-15 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of a beta protein production |
CN1547486A (zh) | 2001-06-26 | 2004-11-17 | 抗opgl抗体 | |
PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
WO2005044780A1 (fr) * | 2003-11-10 | 2005-05-19 | Kyorin Pharmaceutical Co., Ltd. | Derive d'acide aminocarboxylique, son sel d'addition et agent de regulation du recepteur s1p |
EP2234608A2 (fr) | 2007-12-11 | 2010-10-06 | Viamet Pharmaceuticals, Inc. | Inhibiteurs de métalloenzymes utilisant des fractions de liaison à un métal en combinaison avec des fractions de ciblage |
US8476305B2 (en) | 2008-02-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient |
WO2010132494A1 (fr) * | 2009-05-11 | 2010-11-18 | Ghosh Arun K | Composés et méthodes utilisables dans le cadre du traitement du sida et des infections par le vih |
CN103748099B (zh) | 2011-05-19 | 2016-08-17 | 卡洛斯三世国家癌症研究中心基金会 | 作为蛋白激酶抑制剂的大环化合物 |
CN102276546B (zh) * | 2011-05-31 | 2014-06-25 | 中国科学院广州生物医药与健康研究院 | 用作蛋白聚糖酶调节剂的化合物及其应用 |
CN108623530B (zh) * | 2016-09-18 | 2021-05-11 | 广西师范大学 | 1,2,8-氧代二氮杂环壬-9-硫酮衍生物及其合成方法和应用 |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9102635D0 (en) * | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
US5427954A (en) * | 1992-04-29 | 1995-06-27 | Shriner's Hospitals For Crippled Children | Compositions and methods for detection and treatment of human osteoarthritis |
-
1996
- 1996-11-13 IL IL12436696A patent/IL124366A0/xx unknown
- 1996-11-13 SK SK634-98A patent/SK63498A3/sk unknown
- 1996-11-13 WO PCT/US1996/018382 patent/WO1997018207A2/fr not_active Application Discontinuation
- 1996-11-13 HU HU0201479A patent/HUP0201479A2/hu unknown
- 1996-11-13 CA CA002237524A patent/CA2237524A1/fr not_active Abandoned
- 1996-11-13 JP JP9519119A patent/JP2000502050A/ja active Pending
- 1996-11-13 EE EE9800115A patent/EE9800115A/xx unknown
- 1996-11-13 CZ CZ981447A patent/CZ144798A3/cs unknown
- 1996-11-13 BR BR9611563A patent/BR9611563A/pt not_active IP Right Cessation
- 1996-11-13 HR HR08/743,439A patent/HRP960533A2/hr not_active Application Discontinuation
- 1996-11-13 CN CN96198327A patent/CN1202161A/zh active Pending
- 1996-11-13 EP EP96943497A patent/EP0863885A2/fr not_active Withdrawn
- 1996-11-13 PL PL96326714A patent/PL326714A1/xx unknown
- 1996-11-13 SI SI9620120A patent/SI9620120A/sl unknown
-
1998
- 1998-05-13 NO NO982185A patent/NO982185L/no unknown
- 1998-05-14 MX MX9803851A patent/MX9803851A/es unknown
- 1998-07-07 LV LVP-98-104A patent/LV12167B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1997018207A3 (fr) | 1997-07-24 |
WO1997018207A2 (fr) | 1997-05-22 |
LV12167A (lv) | 1998-11-20 |
CN1202161A (zh) | 1998-12-16 |
BR9611563A (pt) | 1999-03-02 |
HRP960533A2 (en) | 1998-04-30 |
JP2000502050A (ja) | 2000-02-22 |
NO982185L (no) | 1998-07-13 |
HUP0201479A2 (en) | 2002-08-28 |
EE9800115A (et) | 1998-10-15 |
PL326714A1 (en) | 1998-10-26 |
LV12167B (en) | 1999-03-20 |
SK63498A3 (en) | 1999-01-11 |
SI9620120A (sl) | 1999-06-30 |
CZ144798A3 (cs) | 1998-10-14 |
NO982185D0 (no) | 1998-05-13 |
MX9803851A (es) | 1998-09-30 |
IL124366A0 (en) | 1998-12-06 |
EP0863885A2 (fr) | 1998-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2237524A1 (fr) | Nouveaux composes macrocycliques tenant lieu d'inhibiteurs de la metalloprotease | |
US5703092A (en) | Hydroxamic acid compounds as metalloprotease and TNF inhibitors | |
US6376665B1 (en) | Amide derivatives as inhibitors of matrix metalloproteinases, TNF-α, and aggrecanase | |
WO1995029892A1 (fr) | Derives d'acides hydroxamiques et d'acides amines et leur utilisation comme agents antiarthritiques | |
US5672598A (en) | Lactam-containing hydroxamic acids | |
US7053081B2 (en) | Cyclic malonamides as inhibitors of A-β protein production | |
US5691381A (en) | Hydroxamic and carbocyclic acids as metalloprotease inhibitors | |
US6455522B1 (en) | Cyclic sulfonamide derivatives as metalloproteinase inhibitors | |
CA2361848A1 (fr) | Nouveaux inhibiteurs de lactame de metalloproteases matricielles, de tnf-alpha, et de l'aggrecanase | |
US6281352B1 (en) | Macrocyclic compounds as metalloprotease inhibitors | |
US6620823B2 (en) | Lactam metalloprotease inhibitors | |
KR20030024915A (ko) | 치마제 저해물로서의 피롤리딘 유도체 및 그 용도 | |
KR19990067592A (ko) | 메탈로프로테아제 억제제로서의 신규한 마크로사이클릭 화합물 | |
AU1272697A (en) | Novel macrocyclic compounds as metalloprotease inhibitors | |
HRP950259A2 (en) | Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |